more_reports

Biotech Initiates Phase III Trial for Heart Disease Drug

  ()
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock.
Tags: Biotechnology / Pharmaceuticals

Breakthrough Therapy Shows Promising Long-Term Results for Depression

  ()
Cybin Inc. (CYBN:NYSE American; CYBN:NEO) has announced positive results from its 12-month Phase 2 study of CYB003, a proprietary deuterated psilocin program designed for the adjunctive treatment of major depressive disorder (MDD). Find out about the FDA's designation of this treatment and why the Chief Medical Officer sees this news as "highly encouraging."
Tags: Psychedelics

Analyst Says Biotech's Data Supports Advancement Into Phase III

Research Report
  ()
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.
Tags: Biotechnology / Pharmaceuticals

Transformative Moves in Harm Reduction Expanding Market Reach with New Partnerships and Acquisitions

  ()
Safe Supply Streaming Co. Ltd (SPLY:CSE; SSPLF:OTCQB; QM4:FSE) recently announced significant developments within its portfolio company, Safety Strips, and a key acquisition. Learn more about how these strategic developments aim to enhance harm reduction efforts and expand market reach.
Tags: Life Sciences Tools & Diagnostics

Opportunity Arises for Co. With Cell Pouch

Research Report
  ()
This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report.
Tags: Medical Devices

Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory

  ()
Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise.
Tags: Biotechnology / Pharmaceuticals

Regenerative Med Co. Granted Second Tissue License

Research Report
  ()
With these expanded capabilities, the biotech may increase revenue generation and continue its clinical trial, noted a Roth MKM report.
Tags: Regenerative Medicine

New Blood Cancer Treatment Shows Continued Response

Research Report
  ()
The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report.
Tags: Regenerative Medicine

Medical Co. Ready for a Transformative F2025

Research Report
  ()
The Leede Financial Inc. analyst also noted that while F2024 is a transition year for Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), F2025 is expected to be transformative for U.S. TULSA-PRO adoption. rates.
Tags: Healthcare ServicesMedical Devices

Revolutionary AI Tools Take Center Stage in Medical Education Symposium

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the release of its newly updated Medical Education Suite (MES). Read more to find out how this update is set to transform medical education and enhance training efficiency.
Tags: Healthcare ServicesMedical Devices

Pharma Stock Has Significant Upside Potential, Analyst Says

Research Report
  ()
"We believe significant upside potential exists," H.C. Wainwright & Co. analysts wrote about Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) in an updated research note.
Tags: Biotechnology / Pharmaceuticals

AI Healthcare Co. With 'Bright' Outlook Closes Placement

  ()
Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million. Find out why one analyst says the stock is a Strong Buy and worth going overweight on.
Tags: Life Sciences Tools & DiagnosticsHealthcare ServicesTechnology

Biotech Shares Positive Phase I Data for Alzheimer's Treatment

Research Report
  ()
Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%.
Tags: Biotechnology / Pharmaceuticals

Mass. Biotech Shares Strong Q3 Results

Research Report
  ()
Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) recently reported strong Q3 2024 earnings, which led to its Outperform rating, according to a Wedbush research note.
Tags: Biotechnology / Pharmaceuticals

Boston Biotech Announces Novartis Collaboration

Research Report
  ()
Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) recently unveiled a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program, according to a Wedbush research note.
Tags: Biotechnology / Pharmaceuticals

Regenerative Medicine Co. May Have Solution to Delivering Cell Treatments

  ()
This Canadian life sciences firm is developing an implantable cell-containing pouch, shown in clinical trial data thus far to be safe, well-tolerated and effective. Learn why several analysts rate the company Buy.
Tags: Regenerative MedicineMedical Devices

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates

Research Report
  ()
DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch.
Tags: Biotechnology / Pharmaceuticals

Silver Break Out Confirmed

Contributed Opinion
  ()
The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell.
Tags: SilverBiotechnology / PharmaceuticalsGold

NY Biopharma Shares Promising Clinical Data

Research Report
  ()
Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.

Research Report
  ()
H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.
Tags: Biotechnology / Pharmaceuticals

Is This AI Healthcare Stock Worth Being Overweight On?

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.
Tags: Healthcare ServicesTechnologyLife Sciences Tools & Diagnostics